Tirzepatide vs Semaglutide Muscle Loss: Which Preserves More Lean Mass?

GLP-1 & Obesity Medicine Guide • Updated October 7, 2026

Semaglutide and tirzepatide can produce substantial weight loss, but an important question follows: How much of the weight lost is fat, and how much is lean mass?

The question is more complicated than it first appears. Studies of semaglutide and tirzepatide show that both treatments reduce fat mass and can also reduce lean mass during weight loss. But lean mass is not synonymous with skeletal muscle, and results from separate trials cannot be treated as a direct head-to-head comparison of muscle preservation.

A 2026 systematic review and meta-analysis of 20 randomized controlled trials involving 15,782 participants estimated that lean mass represented approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide. The analysis also found a more favorable proportion with lifestyle intervention that incorporated resistance training. These figures describe measured lean mass, not percentages of skeletal muscle loss.

Most accurate interpretation:
Current evidence suggests that tirzepatide may have a lower proportion of weight loss coming from lean mass than semaglutide, but there is not yet sufficient direct evidence to conclude that tirzepatide definitively preserves more functional skeletal muscle.

This distinction matters because a person can lose lean mass without losing the same amount of contractile muscle tissue. Preservation of strength, physical function, muscle quality and bone health may ultimately matter more clinically than a DXA-derived lean-mass number alone.

Key Takeaways

  • Both drugs can reduce lean mass during substantial weight loss.
  • Most weight lost is generally fat mass, not lean mass.
  • A 2026 meta-analysis estimated that lean mass accounted for 35.2% of semaglutide-associated weight loss and 25.4% with tirzepatide.
  • Those percentages do not mean 35.2% or 25.4% of skeletal muscle was lost.
  • Direct evidence proving that tirzepatide preserves functional skeletal muscle better than semaglutide remains limited.
  • Resistance training and adequate protein intake are central strategies for improving the quality of weight loss.
  • For people at higher risk of sarcopenia or functional decline, monitoring strength and body composition may be more useful than tracking scale weight alone.

Semaglutide vs Tirzepatide: What Are We Actually Comparing?

Semaglutide is a GLP-1 receptor agonist, whereas tirzepatide activates both the GIP and GLP-1 receptors.

Both medications can reduce appetite and food intake and can produce substantial reductions in body weight. Because body weight is made up of multiple compartments, weight loss generally includes reductions in:

  • Fat mass
  • Lean soft tissue
  • Body water
  • Glycogen-associated water

For this reason, headlines claiming that a particular GLP-1 drug "causes muscle loss" can be misleading when the underlying study actually measured lean body mass using DXA.

Lean Mass Is Not the Same as Muscle Mass

This is the most important concept in the entire comparison.

DXA and other body-composition techniques divide the body into compartments, but lean mass or fat-free mass is not equivalent to skeletal muscle tissue. Lean compartments can include water and other non-fat tissues in addition to muscle.

A 2024 analysis in the Journal of the Endocrine Society emphasized that changes in fat-free mass should not automatically be interpreted as equivalent changes in skeletal muscle. The authors also discussed how some reduction in fat-free mass can accompany substantial reductions in adipose tissue even when the overall clinical result of weight loss is favorable.

Term What it means Why it matters
Lean mass A general non-fat or non-adipose body-composition measure Useful for tracking body composition, but not a direct measure of skeletal muscle alone
Fat-free mass Body mass excluding fat Includes water and multiple tissues, not only muscle
Lean soft tissue A DXA-derived component representing non-fat, non-bone-mineral tissue Commonly reported in body-composition studies but is not identical to skeletal muscle
Skeletal muscle mass Muscle tissue involved in movement and force production More directly relevant to strength and physical function
Muscle strength Ability to produce force Provides functional information that body composition alone cannot provide
Muscle quality Relationship between muscle quantity and performance/function Muscle size alone does not fully describe physical capability

Bottom line: a reported reduction in lean mass should not automatically be translated into the statement that a drug "destroyed muscle."

What Does the Semaglutide Evidence Show?

STEP 1 Body-Composition Analysis

One of the best-known semaglutide body-composition analyses came from an exploratory DXA substudy of the STEP 1 trial.

The substudy included 140 adults with overweight or obesity, of whom 95 received semaglutide 2.4 mg weekly and 45 received placebo. Participants also received lifestyle intervention.

At week 68, the semaglutide group had:

Measure Semaglutide Result
Body weight −15.0%
Total fat mass −19.3%
Regional visceral fat mass −27.4%
Total lean body mass −9.7%
Proportion of body weight represented by lean mass +3.0 percentage points

These findings show an important pattern: fat mass fell substantially more than lean body mass. Although absolute lean body mass decreased, the percentage of total body weight represented by lean body mass actually increased.

That is different from saying that semaglutide caused a 9.7% loss of skeletal muscle.

The analysis was exploratory, involved a relatively small DXA subgroup, and was not designed as a direct semaglutide-versus-tirzepatide muscle trial.

View the STEP 1 body-composition analysis

What Does the Tirzepatide Evidence Show?

SURMOUNT-1 DXA Substudy

A body-composition substudy of SURMOUNT-1 evaluated 160 participants who had DXA measurements at baseline and week 72.

Pooled tirzepatide treatment produced the following changes:

Measure Tirzepatide Result
Body weight −21.3%
Fat mass −33.9%
Lean mass −10.9%
Approximate composition of weight lost 75% fat mass / 25% lean mass

Again, the important point is that most of the weight lost was fat mass.

The study also found broadly similar proportions of fat and lean mass loss across several prespecified subgroups, including different age and sex categories.

However, this was a tirzepatide-versus-placebo DXA substudy, not a semaglutide-versus-tirzepatide randomized body-composition trial.

PubMed: SURMOUNT-1 body-composition study

2026 Meta-Analysis: Semaglutide vs Tirzepatide Lean Mass

The most useful recent comparison comes from a 2026 systematic review and meta-analysis of randomized controlled trials.

The investigators searched PubMed, Embase, Cochrane CENTRAL and Web of Science through January 20, 2026. Twenty randomized controlled trials involving 15,782 participants met the inclusion criteria.

Intervention Estimated proportion of total weight lost represented by lean mass 95% CI
Semaglutide 35.2% 31.5–38.9%
Tirzepatide 25.4% 22.8–28.0%
Liraglutide 26.8% 23.1–30.5%
Lifestyle intervention 26.2% 24.1–28.3%
Lifestyle + resistance training 17.5% 14.2–20.8%

These results are important because the pooled estimate was lower for tirzepatide than semaglutide.

Why the Numbers Do Not Prove Muscle-Preservation Superiority

There are several reasons not to turn the result into an absolute statement that tirzepatide "preserves muscle better."

  1. Different trials: the analysis pooled different populations, treatment durations, protocols and body-composition datasets.
  2. Different endpoint: the outcome was lean mass, which is not equivalent to contractile skeletal muscle.
  3. Different magnitude of weight loss: a treatment producing greater total weight loss may have a different lean-mass percentage even when absolute lean-tissue changes are similar.
  4. Different measurement methods: DXA, MRI, CT and BIA do not measure exactly the same body-composition variables.

The meta-analysis reported moderate heterogeneity, with I² = 68%.

Important: The figures of 35.2% and 25.4% mean the estimated proportion of total weight lost represented by lean mass. They do not mean that semaglutide causes 35.2% muscle loss or that tirzepatide causes 25.4% muscle loss.

PubMed: 2026 systematic review and meta-analysis

What Does the Direct Semaglutide vs Tirzepatide Trial Show?

SURMOUNT-5 is the most important direct randomized comparison of tirzepatide and semaglutide for obesity in adults without type 2 diabetes.

The phase 3b trial randomized 751 adults to maximum tolerated doses of tirzepatide or semaglutide for 72 weeks.

Outcome at Week 72 Tirzepatide Semaglutide
Mean percentage body-weight change −20.2% −13.7%
Mean waist-circumference change −18.4 cm −13.0 cm

Tirzepatide therefore produced greater average weight and waist reduction in this head-to-head trial.

However, SURMOUNT-5 was not primarily designed to determine which treatment preserves skeletal muscle. The principal comparison was body weight, with additional metabolic and clinical outcomes. Therefore, it should not be used as proof that tirzepatide causes less muscle loss than semaglutide.

PubMed: SURMOUNT-5

Does Tirzepatide Preserve More Muscle Than Semaglutide?

The answer depends on what is meant by "preserve more muscle."

Question What the Current Evidence Supports
Do both drugs reduce lean mass during weight loss? Yes.
Do both drugs generally reduce substantially more fat than lean mass? Yes.
Does pooled 2026 evidence show a lower proportion of weight loss as lean mass with tirzepatide? Yes.
Does that prove tirzepatide preserves more skeletal muscle? No.
Is there a definitive head-to-head randomized trial using standardized skeletal-muscle and functional outcomes? Not yet.
Can resistance training improve lean-mass preservation during weight loss? Evidence supports this.

In other words, tirzepatide currently has a favorable signal on the proportion of weight lost as lean mass, but the clinical question remains incompletely answered.

Why Greater Weight Loss Can Complicate the Muscle-Loss Comparison

One of the easiest mistakes is to compare percentages from different trials without considering how much weight each group lost.

In the STEP 1 DXA substudy, semaglutide was associated with approximately 15% body-weight loss and 9.7% lean-body-mass loss.

In the SURMOUNT-1 DXA substudy, tirzepatide was associated with approximately 21.3% body-weight loss and 10.9% lean-mass loss.

Looking only at these percentages could create the misleading impression that tirzepatide necessarily produces less absolute lean-mass loss simply because a greater fraction of its weight loss was fat.

The two studies were not designed as a head-to-head comparison, so these numbers should primarily be used to understand the pattern of body-composition change rather than to rank the medications.

What About Muscle Strength and Physical Function?

Body composition is only part of the story.

A clinically meaningful assessment of muscle health should ideally include:

  • Muscle quantity
  • Muscle quality
  • Muscle strength
  • Physical performance
  • Bone health

This is particularly important because a reduction in lean mass does not automatically mean that a person will experience a meaningful decline in strength or function.

Possible functional measurements include:

  • Handgrip strength
  • Chair-to-stand performance
  • Walking speed
  • Resistance-training performance
  • Other validated physical-function assessments

Current obesity-care and nutrition guidance emphasizes assessing muscle strength and function alongside strategies to optimize protein intake and resistance training.

Who May Have Greater Risk of Clinically Important Muscle Loss?

Not everyone losing weight on semaglutide or tirzepatide has the same risk.

Risk may be more important in people who begin treatment with:

  • Low muscle mass or suspected sarcopenia
  • Advanced age
  • Frailty or low physical activity
  • Inadequate dietary protein
  • Very low calorie intake
  • Rapid or prolonged weight loss
  • Existing functional limitations

This is one reason body weight alone is an incomplete measure of treatment success.

For a person with obesity and significant excess adiposity, substantial fat loss can be clinically beneficial even when some lean mass is lost. For a leaner or older person with little muscle reserve, however, the same magnitude of lean-mass change may have different implications.

How to Preserve Muscle During Semaglutide or Tirzepatide Treatment

The emerging consensus is that the solution is not simply choosing one incretin drug over another.

A more useful strategy is to address nutrition, resistance exercise and monitoring at the same time.

1. Prioritize Adequate Protein

Reduced appetite can make it surprisingly difficult to eat enough protein during GLP-1 therapy.

A multi-society clinical advisory has discussed protein targets in the range of approximately 1.2–1.6 g/kg/day during active weight reduction for appropriate adults, with individualization based on body size, body composition, health status and treatment goals.

For people with obesity, simply multiplying actual body weight by a protein target may overestimate requirements. Adjusted body weight, ideal body weight or fat-free mass may be more appropriate in some circumstances.

The same advisory emphasizes that adequate protein intake alone is unlikely to be sufficient to preserve muscle without structured resistance training.

Practical principle: when appetite is limited, make protein-rich foods an early priority within the meal rather than leaving most of the day's protein until the end of the day.

2. Perform Resistance Training

Resistance training is one of the most important modifiable factors for maintaining lean mass during weight loss.

Current expert guidance supports structured strength training as part of GLP-1-based obesity treatment, customized to the individual's fitness and physical capacity.

A practical starting framework can include:

  • Squats or sit-to-stand variations
  • Hip-hinge movements
  • Rows or pulling exercises
  • Pressing exercises
  • Step-ups or other lower-body movements
  • Progressive resistance as tolerated

Older adults, beginners and people with mobility limitations may require a modified program or professional supervision.

3. Avoid Unnecessarily Aggressive Calorie Restriction

Very low calorie intake can make it more difficult to meet protein and micronutrient needs.

Loss of appetite is an expected pharmacologic effect of incretin therapy, but a person who is consistently unable to eat enough food should discuss the issue with their healthcare professional.

4. Monitor Body Composition When Clinically Appropriate

Body weight is simple, but it cannot tell you whether weight loss is coming primarily from fat, lean tissue or changes in hydration.

Depending on the clinical setting, monitoring may include:

  • DXA: useful for estimating fat mass, lean soft tissue and bone mineral density
  • BIA: practical for repeated measurements, although technique and hydration can affect results
  • CT or MRI: more detailed tissue-level assessment in selected research or clinical settings
  • Strength testing: provides functional information not available from body weight alone
  • Waist circumference: useful for tracking central adiposity

Consistency is important. Comparing measurements from different devices under different conditions can create apparent changes that are partly methodological.

Semaglutide vs Tirzepatide: Does More Weight Loss Mean More Muscle Loss?

Not necessarily.

The relationship between total weight loss and lean-mass change is complex.

A person losing more total body weight may lose more absolute lean tissue simply because the overall magnitude of weight loss is larger, while still having a favorable fat-to-lean loss ratio.

That is why the clinically meaningful target is not "zero lean-mass loss" at all costs.

The goal is high-quality weight loss: substantial reduction in excess fat while maintaining as much muscle mass, strength, physical function and bone health as reasonably possible.

Wegovy vs Zepbound: What Should Patients Know?

Wegovy contains semaglutide, while Zepbound contains tirzepatide.

Searches for "Wegovy vs Zepbound muscle loss" and "semaglutide vs tirzepatide muscle loss" are essentially asking the same underlying body-composition question.

Issue What the Evidence Indicates
Average weight loss Tirzepatide produced greater weight loss than semaglutide in SURMOUNT-5
Fat loss Both substantially reduce fat mass
Lean mass Both reduce lean mass during substantial weight loss
Proportion of weight lost as lean mass Lower pooled estimate with tirzepatide in the 2026 meta-analysis
Proof of superior skeletal-muscle preservation Not established
Resistance training Important for lean-mass preservation regardless of drug
Protein adequacy Important, particularly when appetite is suppressed

What About New Muscle-Sparing Obesity Drugs?

The obesity-drug field is increasingly moving beyond the question of how much weight can be lost toward the question of what type of tissue is lost during treatment.

This has led to research into combination treatments designed to increase fat loss while limiting reductions in lean tissue.

One important example is trevogrumab, an investigational therapy targeting the myostatin/GDF8 pathway.

In an October 1, 2026 update, Regeneron reported new Phase 2 COURAGE results evaluating trevogrumab in combination with semaglutide. In a predefined MRI substudy, the company reported that lower-dose trevogrumab preserved approximately 70% of thigh muscle that otherwise would have been lost with semaglutide alone. DXA analyses also showed greater preservation of lean mass with trevogrumab combinations.

These results are scientifically important, particularly because the program is using both body-composition and muscle-volume measurements. However, the findings are investigational and company-reported at this stage. Trevogrumab is not an approved muscle-preserving obesity treatment, and longer-term evidence concerning strength, physical function, safety and patient-centered outcomes remains important.

The emerging research suggests that the future of obesity treatment may increasingly focus on fat-selective weight loss and preservation of muscle and physical function, rather than the scale number alone.

Regeneron: October 1, 2026 COURAGE update on trevogrumab

How Strong Is the Evidence?

Evidence Question Evidence Level Interpretation
Semaglutide produces substantial weight and fat loss E4 Supported by large randomized clinical trials
Tirzepatide produces substantial weight and fat loss E4 Supported by large randomized clinical trials
Both treatments reduce lean mass during substantial weight loss E3–E4 Supported by body-composition substudy data and evidence syntheses
Tirzepatide has a lower pooled proportion of weight loss represented by lean mass E3 Supported by the 2026 meta-analysis, but based on cross-trial comparisons
Tirzepatide definitively preserves skeletal muscle better than semaglutide E2 Direct comparative evidence remains insufficient
Resistance training helps preserve lean mass during weight loss E4 Supported by broader weight-loss and exercise evidence
Adequate protein supports muscle preservation E3–E4 Supported by clinical nutrition evidence and expert consensus

Evidence levels reflect the strength and directness of evidence for the specific question, not the overall effectiveness of either medication.

Frequently Asked Questions

Does tirzepatide cause less muscle loss than semaglutide?

A 2026 meta-analysis found that lean mass represented approximately 25.4% of weight lost with tirzepatide compared with 35.2% with semaglutide. However, this was a cross-trial pooled analysis rather than a randomized head-to-head body-composition trial, so it does not prove superior preservation of functional skeletal muscle.

Does semaglutide cause muscle loss?

Semaglutide treatment is associated with reductions in lean body mass during substantial weight loss. In the STEP 1 DXA substudy, total lean body mass decreased by 9.7%, while fat mass decreased by 19.3%. The lean-mass finding should not be interpreted as an equivalent percentage loss of skeletal muscle.

Does tirzepatide cause muscle loss?

Tirzepatide is also associated with reductions in lean mass during weight loss. In the SURMOUNT-1 DXA substudy, lean mass declined by 10.9%, while fat mass declined by 33.9%. Approximately 75% of body weight lost was fat mass and 25% lean mass.

Which GLP-1 is best for preserving muscle?

Current evidence does not establish a definitive winner for functional skeletal-muscle preservation. Available data suggest a lower proportion of weight loss as lean mass with tirzepatide, but direct comparative measurements of skeletal muscle quantity, quality and physical function remain limited.

Can you build muscle while taking semaglutide or tirzepatide?

Muscle gain may be possible, particularly when resistance training and adequate nutrition are maintained, but the degree of muscle gain depends on factors including training status, protein intake, energy balance, age and overall health. During active weight loss, the immediate goal for many people is often preservation rather than rapid muscle gain.

How much protein should I eat on a GLP-1?

Several expert recommendations discuss approximately 1.2–1.6 g/kg/day during active weight reduction, but the appropriate calculation method varies, particularly in people with obesity, kidney disease or other medical conditions. A clinician or dietitian can individualize the target.

Does resistance training help prevent GLP-1 muscle loss?

Yes. Resistance training is one of the principal evidence-supported strategies for preserving lean mass and physical function during weight reduction and is recommended as part of a comprehensive approach to GLP-1-based obesity treatment.

Is lean mass loss always harmful?

No. Lean-mass measurements include more than skeletal muscle, and substantial weight loss can change multiple body compartments. Clinical significance depends on muscle strength, physical function, baseline muscle reserve, age, nutritional status and other factors.

The Bottom Line

Semaglutide and tirzepatide both produce substantial fat loss and both can reduce lean mass during weight reduction.

The strongest current comparative signal comes from a 2026 meta-analysis in which approximately 35.2% of weight lost with semaglutide and 25.4% with tirzepatide was estimated to consist of lean mass.

That finding is important, but it should not be turned into a simplistic statement that "tirzepatide does not cause muscle loss" or that it has conclusively been proven to preserve skeletal muscle better than semaglutide.

The evidence supports a more precise conclusion:

Both drugs can reduce lean mass during major weight loss. Tirzepatide shows a lower pooled proportion of weight loss as lean mass than semaglutide, but whether that translates into superior preservation of actual skeletal muscle, strength and physical function remains uncertain.

For people using either medication, the modifiable factors may ultimately matter more than focusing exclusively on the drug comparison: adequate protein intake, progressive resistance training, avoiding unnecessary nutritional restriction and monitoring body composition and physical function when appropriate.

References & Primary Sources

  1. Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026;28(6):4818–4827. DOI: 10.1111/dom.70666. PubMed.
  2. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025;393:26–36. DOI: 10.1056/NEJMoa2416394. PubMed / SURMOUNT-5.
  3. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025;27(5):2720–2729. DOI: 10.1111/dom.16275. PubMed.
  4. Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society. 2021;5(Suppl 1):A16–A17. DOI: 10.1210/jendso/bvab048.030. Full article.
  5. Tinsley GM, Heymsfield SB. Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society. 2024;8(11):bvae164. DOI: 10.1210/jendso/bvae164.
  6. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Clinical Nutrition. 2025;122(1):344–367. DOI: 10.1016/j.ajcnut.2025.04.023. PubMed.
  7. Regeneron Pharmaceuticals. Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss. October 1, 2026. Company release.

Tools and Telehealth

If you need a clinician to review symptoms, laboratory results or a GLP-1 treatment plan, The Wellness Company virtual care is one telehealth pathway. Availability, eligibility and prescribing decisions are determined by licensed clinicians.

Strength training at home: resistance-band sets can support the resistance-training approach described above.

Protein and portion tracking: a digital kitchen scale can make meal-level protein estimation easier.

GLP-1 Knowledge graph: GLP-1 & Peptide Hub → Starting GLP-1 → muscle loss → bone density → nutrient monitoring → stopping GLP-1 → personalized treatment → Next generation (GLP 2.0)

Medical Disclaimer

This article is for educational purposes and does not provide individualized medical advice. Do not change, stop or combine prescription medicines based solely on information in this article.

Protein targets, exercise programs and body-composition monitoring should be individualized, particularly for people who are older, frail, undernourished or living with kidney disease or other chronic conditions.

Always discuss prescription GLP-1 or GIP/GLP-1 treatment decisions with an appropriately qualified healthcare professional.

Affiliate disclosure: Some links on this page may be affiliate links. OneDayMD may receive a commission if a reader makes a qualifying purchase, at no additional cost to the reader. Editorial conclusions are not determined by affiliate relationships.

Comments

Labels

Show more

Archive

Show more

Popular posts from this blog

GLP-1 Hub: Approved Drugs, Pills vs Injections, Retatrutide & Side Effects

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

GLP-1 Muscle Loss: How to Preserve Lean Mass, Strength & Metabolic Health

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2026)

Top Smart Glasses for the Visually Impaired (2026): eSight, Envision, OrCam & More

Fenbendazole, Ivermectin and Mebendazole for Cancer: Case Series of 800+ Case Reports (November 2026 Update)

Ivermectin, Fenbendazole and Mebendazole: A Peer-Reviewed Protocol for Cancer Treatment (2026 Update)

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

How to Get Ivermectin in the US: Pharmacies, Legal Status & State-by-State Access (2026)

Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types (2026)